Pharma channel feed

Drug­mak­ers pull back af­ter Covid boom, plan­ning to cut costs as they pre­pare for in­dus­try’s next era

Last year
R&D
Coronavirus

Up­dat­ed: Il­lu­mi­na's $7.1B Grail deal be­ing in­ves­ti­gat­ed by SEC

Last year

En­do sues Zy­dus in patent bat­tle over meth­ods of pu­ri­fy­ing gener­ic ver­sion of re­called smok­ing ces­sa­tion drug Chan­tix

Last year
Law

Drug price in­creas­es lay­ered over decades: AARP analy­sis shows how list prices can rise by more than 700%

Last year
Law

As­traZeneca, PhRMA sue Louisiana in fed­er­al court over state 340B drug ac­cess law

Last year
Law

RSV mar­ket­ing bat­tle shap­ing up with GSK and Pfiz­er cam­paigns run­ning on TV, dig­i­tal chan­nels ahead of the vi­ral sea­son

Last year
Marketing

FDA lays out post­mar­ket­ing ap­proach­es for da­ta col­lec­tion from un­der­rep­re­sent­ed groups

Last year
FDA+

No­vo Nordisk an­tic­i­pates patchy We­govy sup­ply in the com­ing months as it pro­vides in­sight on man­u­fac­tur­ing plans

Last year
Manufacturing

J&J re­ceives fifth FDA nod for treat­ing mul­ti­ple myelo­ma, with boxed warn­ing and REMS in tow

Last year
R&D
FDA+

Ex­clu­sive: As­traZeneca’s out­go­ing R&D chief Mene Pan­ga­los re­flects on a 14-year R&D turn­around and the in­dus­try's fu­ture

Last year
People
R&D

No­vo Nordisk boasts $14.6B in H1 obe­si­ty, di­a­betes sales, but ques­tions linger on broad­er cov­er­age

Last year

Galera Ther­a­peu­tics to cut 70% of staff in wake of re­jec­tion for ra­dio­ther­a­py com­pli­ca­tion treat­ment

Last year
FDA+

Genen­tech, Blue­print tout full ap­proval for Gavre­to in rare type of lung can­cer

Last year
FDA+

More lab and man­u­fac­tur­ing space com­ing to the UK's 'Gold­en Tri­an­gle'

Last year
Manufacturing

Texas at­tor­ney gen­er­al an­nounces $42.7M set­tle­ment with Take­da, Bax­ter over AD­HD drug 

Last year
Law

Genen­tech adopts racial jus­tice lens for new fund­ing that goes be­yond typ­i­cal health eq­ui­ty grants

Last year
Marketing

OTC nalox­one nasal spray to cost about as much as the brand-name, pre­scrip­tion ver­sion

Last year

No­vavax plans to have up­dat­ed Covid vac­cine to mar­ket by Sep­tem­ber — but will it be ready in time?

Last year
Coronavirus

Evo­lus puts on 'y­outh­ful' new look for frown line treat­ment Jeu­veau

Last year
Marketing

Zyn­te­glo and Skysona com­bine for 16 pa­tient starts since ap­provals last year

Last year

Mar­ket­ingRx roundup: An­a­lyst group finds no ‘ob­vi­ous’ link to GLP-1s and sui­ci­dal ideation; Am­gen de­buts new Pro­lia TV ad

Last year
Marketing

Bris­tol My­ers in­tro­duces re­al pa­tients in dig­i­tal and so­cial So­tyk­tu pso­ri­a­sis cam­paign

Last year
Marketing

FDA's up­dat­ed rules for drug ad­ver­tis­ing for TV and ra­dio near the fin­ish line

Last year
Marketing

Up­dat­ed: Lil­ly's rev­enues rise 28% in Q2 thanks to surge in de­mand for di­a­betes drug Moun­jaro

Last year
First page Previous page 109110111112113114115 Next page Last page
A service from the Financial Times